GAMA
FOLD

Graticule Asia Macro Advisors’s Amicus Therapeutics FOLD Stock Holding History

Graticule Asia Macro Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-385,000
Closed -$4.8M – 97
2019
Q2 		$4.8M Buy
+385,000
New +$4.89M 0.26% 68

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Graticule Asia Macro Advisors's FOLD Position: Q2 2021 in Review

Graticule Asia Macro Advisors sold out of Amicus Therapeutics (FOLD) in Q2 2021, closing a stake of 63,000 shares — an estimated $622K sold.

Graticule Asia Macro Advisors first reported a position in FOLD in Q1 2021 and held it in 1 quarter. The position peaked at $622K in Q1 2021. 235 funds tracked by Wall St. Rank hold FOLD as of Q2 2021.

  • Graticule Asia Macro Advisors reported no remaining Amicus Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Graticule Asia Macro Advisors sold 63,000 Amicus Therapeutics shares in Q2 2021, an estimated $622K.
  • Graticule Asia Macro Advisors first reported a position in Amicus Therapeutics in Q1 2021 and held it in 1 quarter.
  • Graticule Asia Macro Advisors's Amicus Therapeutics position peaked at $622K in Q1 2021.
  • 235 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2021.

Based on Graticule Asia Macro Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.